US EditionFirst patient dosed in Phase 1 trial testing AML T-cell treatment
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
First patient dosed in Phase 1 trial testing AML T-cell treatment
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid leukemia (AML), a form of blood cancer — has been dosed, according to the company. “The completion of first-in-human dosing represents a clinical development milestone for CER-1236,” Robert Sikorski, MD, PhD, chief medical officer of Cero, said in a company press release. About 18 adults wi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
